Everest Medicines

About Everest Medicines

Everest Medicines is a Hong Kong-listed (HKEX 1952.HK) biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines to address critical unmet medical needs for patients in Greater China and other Asian Pacific markets.

Products & Services

Pipeline and Major Products:Includes the company's main pharmaceutical products and development pipeline.

Discovery:Focuses on the research and discovery of new pharmaceutical solutions.

Manufacturing:Covers the production processes for their pharmaceutical products and vaccines.

EVER001:A novel BTK inhibitor for the treatment of primary membranous nephropathy, currently in clinical trials.

AI-Powered mRNA Platform:A proprietary platform for developing mRNA-based therapies and vaccines.

Specialties

Pharmaceutical product development Vaccine development AI-powered mRNA technology Treatment for unmet medical needs in Greater China and Asia Pacific

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Share Placement T: - FT: Share Placement	A: 1572500000 MR: - FA: approximately HK$1,572.50 million FAN: 1572500000	D: 2025-07-25 FD: 2025-07-25	1 investors

Share Placement Latest

2025-07-25

$1.6B

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

W

Wei Fu

Chairman, Executive Director

R

Rogers Yongqing Luo

Chief Executive Officer

I

Ian Woo

President and Chief Financial Officer

H

Honggang Feng

Non-Executive Director

W

William Ki Chul Cho

Non-Executive Director

S

Shidong Jiang

Independent Non-Executive Director

View 10 more team members with Pro

Unlock Full Team Directory

Recent News